Brinsupri
Pronunciation: Brin-sup-ri
Generic name: brensocatib
Dosage form: oral tablets (10 mg, 25 mg)
What is Brinsupri?
Brinsupri is used to treat non-cystic fibrosis bronchiectasis (NCFB) in adults and children 12 years and older. It is an oral tablet taken once a day.
Brinsupri works by blocking dipeptidyl peptidase 1 (DPP1), an enzyme that activates destructive proteins in neutrophils (immune cells). In chronic lung diseases like bronchiectasis, neutrophils accumulate in airways and release activated proteins that cause lung damage and inflammation. By inhibiting DPP1, Brinsupri prevents activation of these damaging proteins, reducing lung destruction and inflammation in neutrophil-driven conditions. Brinsupri belongs to the drug class called DPP1 inhibitors.
Brinsupri (brensocatib) gained FDA approval on August 12, 2025, based on positive results from the Phase 3 ASPEN (NCT04594369) clinical trial, which showed a significant reduction in pulmonary exacerbation rate and lung function decline in adults with non-cystic fibrosis bronchiectasis.
Side effects
The most common side effects of Brinsupri are:
- upper respiratory tract infections
- headache
- rash
- dry skin
- small areas of skin thickening (hyperkeratosis)
- high blood pressure (hypertension).
Less common side effects include abnormal liver blood tests, hair loss (alopecia) and skin cancers.
Serious side effects and warnings
Brinsupri may cause serious side effects, including:
- Skin problems. Tell your healthcare provider about any new skin symptoms. Your healthcare provider may send you to a dermatologist for an examination, if needed.
- Dental problems. Get regular dental checkups while taking BRINSUPRI. Brush and clean your teeth as recommended by your dentist. Tell your healthcare provider and contact your dentist if you experience new gum (gingival) or teeth (dental) symptoms
Using Brinsupri together with live attenuated vaccines has not been studied. It is unknown whether giving live attenuated vaccines during Brinsupri treatment will affect the safety or effectiveness of these vaccines. Patients receiving this medicine should avoid live attenuated vaccines.
It is not known if Brinsupri is safe and effective in children under 12 years of age.
This is not a complete list of side effects, and others may occur. Talk to your healthcare provider about what to expect from Brinsupri. Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Related/similar drugs
Before taking
Before taking Brinsupri, tell your healthcare provider about all your medical conditions, including if you have:
- have recently received or are scheduled to receive any live attenuated vaccinations
- are pregnant or plan to become pregnant. It is not known if Brinsupri will harm your unborn baby
- are breastfeeding or plan to breastfeed. It is not known if Brinsupri passes into your breast milk.
How do I take Brinsupri?
Take Brinsupri exactly as your healthcare provider tells you to take it.
- Take 1 Brinsupri tablet by mouth daily with or without food.
What happens if I miss a dose?
If you forget to take a dose of Brinsupri, take your next dose at your regular time the next day. Do not double the dose to make up for the missed dose.
Dosing information
Dose of Brinsupri for non-cystic fibrosis bronchiectasis in adults and children
- 10 mg or 25 mg once daily.
- Take with or without food.
What other drugs will affect Brinsupri?
Tell your doctor and pharmacist what prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Your doctor may need to change the doses of your medications or monitor you carefully for side effects.
- Strong CYP3A4 and P-gp inhibitors (like the antibiotic clarithromycin): Can increase Brinsupri levels by 55-68%
- Moderate CYP3A4 and P-gp inhibitors (like the heart medication verapamil): Can increase Brinsupri levels by 32-53%
- Strong CYP3A4 inducers (like the tuberculosis drug rifampin): Can decrease Brinsupri levels by 15-33%.
Acid-reducing agents (like esomeprazole)and CYP3A4 substrates (like midazolam) have no effect on Brinsupri levels.
This is not a complete list of interactions. See the Brinsupri Prescribing Information for a complete list.
Storage
Store Brinsupri at room temperature between 68°F to 77°F (20°C to 25°C). Keep it in its original bottle.
Keep out of the reach of children.
Ingredients
Active ingredient: brensocatib
Inactive ingredients: dibasic calcium phosphate dihydrate, glyceryl dibehenate, microcrystalline cellulose, silicon dioxide, and sodium starch glycolate.
Film coating contains ferrosoferric oxide/black iron oxide, iron oxide yellow, and iron oxide red (10 mg) or ferrosoferric oxide/black iron oxide (25 mg), macrogol/PEG, polyvinyl alcohol-partially hydrolyzed, talc, and titanium dioxide.
Available as 10 mg and 25 mg tablets.
Manufacturer
Brinsupri is manufactured for Insmed Incorporated, Bridgewater, NJ 08807.
More about Brinsupri (brensocatib)
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
